05 (−0.01, 0.10) 1.38 (1.19, 1.56) 1.02 (0.85, 1.19) 0.69 (0.56, 0.82)  p value 0.34 <0.001 <0.001 <0.001 p value indicates difference between the isoflavone and placebo groups assessed Temsirolimus in vivo by two-sample t test Table 3 Mean percentage changes (SD) of BMD from baseline in lumbar spine and total proximal femur in the isoflavone and placebo groups at each visit Measurement Follow-up (weeks) Isoflavone Placebo Difference p valuea p valueb p value for time trendc

Mean percentage change (SD) (N) Mean percentage change (SD) (N) Mean (95% CI) Lumbar spine 24 0.24 (3.25) (205) −0.04 (3.14) (205) 0.27 (−0.35, 0.89) 0.38 0.42 <0.001 48 −0.29 (3.12) (202) −0.55 (3.52) (199) 0.26 (−0.39, 0.91) 0.43 72 −1.14 (3.58) (200) −0.92 (3.96) (199) −0.23 (−0.97, 0.52) 0.55 96 −1.09 (3.95) (200) −1.72 (4.12) (199) 0.63 (−0.17, 1.42) 0.12 Total proximal femur 24 −0.02 (2.63) (136) −0.13 (2.43) (136) 0.11 (−0.49, 0.71) 0.72 0.39 <0.001 48 −0.0004 (2.93) (133) −0.40

(2.72) (133) 0.40 (−0.28, 1.08) 0.25 72 CHIR-99021 in vitro −0.13 (3.31) (129) −0.12 (3.85) (130) −0.004 (−0.88, 0.88) 0.99 96 −0.81 (3.59) (133) −1.35 (2.67) (132) 0.54 (−0.23, 1.30) 0.17 a p value denotes the this website comparison of mean percentage changes from respective baseline between the isoflavone and placebo groups by two-sample t test b p value indicates the comparison of mean percentage change from respective baseline between the isoflavone and placebo groups using the generalized estimating equation (GEE) methods to control for time effect in the repeated measurement c p value for time trend denotes the repeated measurement of time trend in the GEE model BMD bone mineral density Table 4 Mean percentage changes (SD) of BMD from baseline in lumbar spine and total proximal femur in the isoflavone and placebo groups at each visit Measurement Follow-up triclocarban (weeks) Isoflavone Placebo Difference p valuea p valueb p value for time trendc Mean percentage change (SD) (N) Mean percentage change (SD) (N) Mean (95% CI) Lumbar spine  NTUH 24 −0.14 (3.56) (68) −0.21 (3.40)

(68) 0.07 (−1.11, 1.26) 0.90 0.65 0.001 48 −0.12 (3.58) (67) −0.22 (3.58) (66) 0.10 (−1.13, 1.32) 0.88 72 −0.96 (3.75) (66) −0.22 (4.31) (66) −0.73 (−2.12, 0.66) 0.30 96 −1.04 (4.18) (67) −1.13 (4.49) (66) 0.09 (−1.40, 1.57) 0.91  CCH 24 0.18 (3.20) (70) −0.12 (2.39) (65) 0.30 (−0.67, 1.26) 0.55 0.79 0.001 48 −0.64 (2.53) (69) −1.27 (3.12) (63) 0.63 (−0.35, 1.62) 0.21 72 −2.16 (3.02) (68) −1.64 (3.50) (63) −0.52 (−1.64, 0.61) 0.37 96 −1.81 (3.41) (68) −2.43 (3.47) (63) 0.62 (−0.57, 1.81) 0.30  NCKUH 24 0.68 (2.94) (67) 0.20 (3.50) (72) 0.48 (−0.61, 1.57) 0.39 0.62 <0.001 48 −0.08 (3.19) (66) −0.21 (3.75) (70) 0.12 (−1.06, 1.31) 0.84 72 −0.29 (3.71) (66) −0.92 (3.94) (70) 0.63 (−0.67, 1.93) 0.34 96 −0.40 (4.15) (65) −1.64 (4.26) (70) 1.24 (−0.19, 2.67) 0.09 Total proximal femur  CCH 24 −0.25 (3.12) (69) −0.32 (3.05) (64) 0.07 (−0.98, 1.13) 0.89 0.06 0.001 48 0.09 (3.65) (68) −0.79 (3.42) (63) 0.87 (−0.35, 2.10) 0.16 72 0.39 (4.16) (64) 0.004 (5.29) (60) 0.